Informatics and standards for nanomedicine technology

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 3, Issue 5, 2011, Pages 511-532

  Thomas, Dennis G ^a   Klaessig, Fred ^b   Harper, Stacey L ^c   Fritts, Martin ^d   Hoover, Mark D ^e   Gaheen, Sharon ^f   Stokes, Todd H ^g   Reznik Zellen, Rebecca ^h   Freund, Elaine T ⁱ   Klemm, Juli D ^j   Paik, David S ^k   Baker, Nathan A ^a  

^a PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^b Pennsylvania Bio Nano Systems   (United States)

^c Oregon State University   (United States)

^d SAIC FREDERICK INC   (United States)

^e NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^f SCIENCE APPLICATIONS INTERNATIONAL CORPORATION   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h University of Massachusetts   (United States)

ⁱ 3rd Millenium Inc   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

^k STANFORD UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL RESEARCH; CHEMICAL COMPOSITIONS; DATA QUALITY; DATA SHARING; DATA-COMMUNICATION; HIGH-DIMENSIONAL; INFORMATICS; INFORMATION RESOURCE; INFORMATION STANDARDS; INTERPRETATION OF DATA; MACHINE LEARNING TECHNIQUES; MINIMUM INFORMATION; NANOMATERIAL; PUBLIC DOMAINS; REPRODUCIBILITIES; UNITED STATES OF AMERICA;

CHARACTERIZATION; CHEMICAL ANALYSIS; INFORMATION MANAGEMENT; INFORMATION USE; MEDICAL NANOTECHNOLOGY; NANOSTRUCTURED MATERIALS; ONTOLOGY; SEMANTICS; SYNTHESIS (CHEMICAL);

STANDARDS;

CONTRAST MEDIUM; DOXORUBICIN; NANOPARTICLE;

ARTICLE; BIOASSAY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER PROGRAM; COMPUTER SIMULATION; CYTOTOXICITY; DATA ANALYSIS; FUNCTIONAL ANATOMY; GENE EXPRESSION; GENETIC TOXICOLOGY; GENETICS; HUMAN; IMMUNOTOXICITY; INFORMATION SERVICE; KNOWLEDGE BASE; MEDICAL INFORMATICS; MEDICAL INFORMATION SYSTEM; MEDICAL LITERATURE; MEDICAL RESEARCH; MESH HEADING; MOLECULAR SIZE; MOLECULAR WEIGHT; NANOMEDICINE; NANOMEDICINE ONTOLOGY; NANOTOXICOLOGY; NATIONAL HEALTH ORGANIZATION; NOMENCLATURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL SAFETY; OXIDATIVE STRESS; PARTICLE SIZE; PEER REVIEW; POLICY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY CONTROL; RELIABILITY; REPRODUCIBILITY; SEMANTICS; SOCIAL NETWORK; SOLUBILITY; STANDARD; TAXONOMY; ZEBRA FISH; CONTROLLED VOCABULARY; FACTUAL DATABASE; PROCEDURES; STANDARDS;

BIOMEDICAL RESEARCH; DATABASES, FACTUAL; NANOMEDICINE; VOCABULARY, CONTROLLED;

EID: 80052267228     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.152     Document Type: Article

References (93)

1. Schmidt KF. Nanofrontiers: vision for the future of nanotechnology. Project of Emerging Technologies (PEN) 2007.
2. Gordon N, Sagman U. Nanomedicine taxonomy. Briefing Paper, Canadian Nanobusiness Alliance 2003.
3. European Technology Platform. Vision paper and basis for a strategic research agenda for nanomedicine. Nanomedicine-Nanotechnology for Health 2005.
4. European Technology Platform. Strategic research agenda for nanomedicine. Nanomedicine-Nanotechnology for Health 2006.
5. Hobson DW. Commercialization of nanotechnology. Wiley Interdiscip Rev: Nanomed Nanobiotechnol 2009, 1:189-202. doi:10.1002/wnan.028.
6. Amiji MM, ed. Nanotechnology for Cancer Therapy. Boca Raton: CRC Press; 2007.
7. Wang X, Wang Y, Chen ZG, Shin DM. Advances of cancer therapy by nanotechnology. Cancer Res Treat 2009, 41:1-11. doi:10.4143/crt.2009.41.1.1.
8. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7:653-664. doi:10.1038/nrclinonc.2010.139.
9. Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Disc Today 2010, 15:842-850. doi:10.1016/ j.drudis.2010.08.006.
10. Godin B, Sakamoto JH, Serda RE, Grattoni A, Bouamrani A, Ferrari M. Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trend Pharmacol Sci 2010, 31:199-205. doi:10.1016/j.tips.2010.01.003.
11. Buxton DB. Current status of nanotechnology approaches for cardiovascular disease: a personal perspective. Wiley Interdiscip Rev: Nanomed Nanobiotechnol 2009, 1:149-155. doi:10.1002/wnan.008.
12. Swai H, Semete B, Kalombo L, Chelule P, Kisich K, Sievers B. Nanomedicine for respiratory diseases. Wiley Interdiscip Rev: Nanomed Nanobiotechnol 2009, 1:255-263. doi:10.1002/wnan.033.
13. Pickup JC, Zhi ZL, Khan F, Saxl T, Birch DJS. Nanomedicine and its potential in diabetes research and practice. Diabetes-Metabolism Res Rev 2008, 24:604-610. doi:10.1002/dmrr.893.
14. Murday JS, Siegel RW, Stein J, Wright JF. Translational nanomedicine: status assessment and opportunities. Nanomed Nanotechnol Biol Med 2009, 5:251-273. doi:10.1016/j.nano.2009.06.001.
15. De Jong WH, Borm PJA. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed 2008, 3:133-149.
16. Cattaneo AG, Gornati R, Sabbioni E, Chiriva-Internati M, Cobos E, Jenkins MR, Bernardini G. Nanotechnology and human health: risks and benefits. J Appl Toxicol 2010, 30:730-744. doi:10.1002/jat.1609.
17. Ray PC, Yu HT, Fu PP. Toxicity and environmental risks of nanomaterials: challenges and future needs. J Environ Sci Health: Part C-Environ Carcinogenesis Ecotoxicol Rev 2009, 27:1-35. doi:10.1080/ 10590500802708267.
18. Hoover MD, Armstrong T, Blodgett T, Fleeger AK, Logan PW, McArthur B, Middendorf PJ. Confirming our industrial hygiene decision-making framework. Synergist 2011, 22:10.
19. Fadeel B, Garcia-Bennett AE. Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv Drug Delivery Rev 2010, 62:362-374. doi:10.1016/j.addr.2009.11.008.
20. Xie J, Lee S, Chen XY. Nanoparticle-based theranostic agents. Adv Drug Delivery Rev 2010, 62:1064-1079. doi:10.1016/j.addr.2010.07.009.
21. Kim K, Kim JH, Park H, Kim YS, Park K, Nam H, Lee S, Park JH, Park RW, Kim IS, et al. Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Rel 2010, 146:219-227. doi:10.1016/j.jconrel.2010.04.004.
22. Bharali DJ, Mousa SA. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol Therapeut 2010, 128:324-335. doi:10.1016/j.phar mthera.2010.07.007.
23. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006, 24:1211-1217. doi:10.1038/Nbt1006/1211.
24. McNeil SE. Unique benefits of nanotechnology to drug delivery and diagnostics. Methods Mol Biol 2011, 697:3-8. doi:10.1007/978-1-60327-198-1-1.
25. Wu XA, Mansour HM. Nanopharmaceuticals II: application of nanoparticles and nanocarrier systems in pharmaceutics and nanomedicine. Int J Nanotechnol 2011, 8:115-145. doi:10.1504/IJNT.2011.037173.
26. Kim DK, Dobson J. Nanomedicine for targeted drug delivery. J Mater Chem 2009, 19:6294-6307. doi:10. 1039/b902711b.
27. Cooper ER. Nanoparticles: a personal experience for formulating poorly water soluble drugs. J Control Rel 2010, 141:300-302. doi:10.1016/j.jcon rel.2009.10.006.
28. LaRocque J, Bharali DJ, Mousa SA. Cancer detection and treatment: the role of nanomedicines. Mol Biotechnol 2009, 42:358-366. doi:10.1007/s12033-009-9161-0.
29. Streicher RM, Scbmidt M, Fiorito S. Nanosurfaces and nanostructures for artificial orthopedic implants. Nanomedicine 2007, 2:861-874. doi:10.2217/1743 5889.2.6.861.
30. Verma S, Domb AJ, Kumar N. Nanomaterials for regenerative medicine. Nanomedicine (Lond) 2011, 6:157-181. doi:10.2217/nnm.10.157.
31. Jain KK. Nanomedicine: application of nanobiotechnology in medical practice. Med Principles Pract 2008, 17:89-101. doi:10.1159/000112961.
32. Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Delivery Rev 2006, 58:1456-1459. doi:10.1016/j.addr.2006.09.011.
33. Sandhiya S, Dkhar SA, Surendiran A. Emerging trends of nanomedicine-an overview. Fund Clin Pharmacol 2009, 23:263-269. doi:10.1111/j1472-82062009.00692.x
34. Freitas RA. What is nanomedicine? Nanomedicine 2005, 1:2-9.
35. Dahl JA, Maddux BLS, Hutchison JE. Toward greener nanosynthesis. Chem Rev 2007, 107:2228-2269. doi:10.1021/Cr050943k.
36. Mckenzie LC, Hutchison JE. Green nanoscience. Chim Oggi-Chem Today 2004, 22:30-33.
37. Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG. Particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol Sci 2007, 95:300-312. doi:10.1093/toxsci/kfl165.
38. National Nanotechnology Initiative. Strategy for nanotechnology-related environmental, health, and safety research. 2008. Available at: (Accessed May 13, 2011).
39. Collen MF. Fifty years in medical informatics. Methods Inform Med 2006, 45:174-179.
40. D'Avolio LW, Farwell WR, Fiore LD. Comparative Effectiveness Research and Medical Informatics. Am J Med 2010, 123:E32-E37. doi:10.1016/ j.amjmed.2010.10.006.
41. Branstetter BF. Basics of imaging informatics: part 2. Radiology 2007, 244:78-84. doi:10.1148/radiol.2441 060995.
42. Peng HC. Bioimage informatics: a new area of engineering biology. Bioinformatics 2008, 24:1827-1836. doi:10.1093/bioinformatics/btn346.
43. Branstetter BF. Basics of imaging informatics: part 1. Radiology 2007, 243:656-667.
44. Luscombe NM, Greenbaum D, Gerstein M. What is bioinformatics? A proposed definition and overview of the field. Methods Inform Med 2001, 40:346-358.
45. Wishart DS. Introduction to cheminformatics. Curr Protoc Bioinform 2007, 14:11. doi:10.1002/04712509 53.bi1401s18.
46. Friede A. Grand challenges in medical informatics. J Am Med Inform Assoc 1995, 2:136-136.
47. Ruping K, Sherman BW. Nanoinformatics: emerging computational tools in nano-scale research. Nsti Nanotech 2004, Tech Proc 2004, 3:525-528.
48. De La Iglesia D, Chiesa S, Kern J, Maojo V, Martin-Sanchez F, Potamias G, Moustakis V, Mitchell JA. Nanoinformatics: new challenges for biomedical informatics at the nano level. Stud Health Technol Inform 2009, 150:987-991.
49. Maojo V, Martin-Sanchez F, Kulikowski C, Rodriguez-Paton A, Fritts M. Nanoinformatics and DNA-based computing: catalyzing nanomedicine. Pediatr Res 2010, 67:481-489. doi:10.1203/PDR.0b013e3181d6245e.
50. Chiesa S, De La Iglesia D, Crespo J, Martin-Sanchez F, Kern J, Potamias G, Maojo V. European efforts in nanoinformatics research applied to nanomedicine. Stud Health Technol Inform 2009, 150:757-761.
51. Buetow KH. Enabling personalized medicine through an interoperable IT infrastructure: an overview of the cancer Biomedical Informatics Grid (R). Personal Med 2009, 6:439-448. doi:10.2217/Pme.09.18.
52. Fenstermacher D, Street C, McSherry T, Nayak V, Overby C, Feldman M. The cancer biomedical informatics grid (caBIG (TM)). 2005 27th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Vols 1-7, 2005, 743-746.
53. de la Iglesia D, Harper S, Hoover MD, Klaessig F, Lippell P, Maddux B, Morse J, Nel A, Rajan K, Reznik-Zellen R, et al. Nanoinformatics 2020 Roadmap, 2010. Available at: (Accessed May 13, 2011).
54. Miller AL, Hoover MD, Mitchell DM, Stapleton BP. The nanoparticle information library (NIL): a prototype for linking and sharing emerging data. J Occupat Environ Hygiene 2007, 4:D131-D134. doi:10.1080/15459620701683947.
55. Klimeck G, McLennan M, Brophy SB, Adams GB, Lundstrom MS. nanoHUB.org: advancing education and research in nanotechnology. Comp Sci Eng 2008, 10:17-23.
56. Lundstrom M. Nanotechnology and cyberinfrastructure: the nanoHUB experience. 2008 17th Biennial University/Government/Industry Micro-Nano Symposium, Proceedings, 2008, 111.
57. Monica JC. Nanotechnology Law. Eagan, MN: West; 2010.
58. Hodge G, Bowman D, Maynard A, eds. International Handbook On Regulating Nanotechnologies. Cheltenham: Edward Elgar; 2010.
59. Nelson SJ, Schopen M, Savage AG, Schulman JL, Arluk N. The MeSH translation maintenance system: structure, interface design, and implementation. Stud Health Technol Inform 2004, 107:67-69.
60. Rubin DL, Shah NH, Noy NF. Biomedical ontologies: a functional perspective. Brief Bioinform 2008, 9:75-90. doi:10.1093/Bib/Bbm059.
61. de Coronado S, Haber MW, Sioutos N, Tuttle MS, Wright LW. NCI thesaurus: using science-based terminology to integrate cancer research results. Medinfo 2004: Proceedings of the 11th World Congress on Medical Informatics, Pt 1 and 2 2004, 107:33-37.
62. Musen MA. Dimensions of knowledge sharing and reuse. Comp Biomed Res 1992, 25:435-467.
63. Gruber TR. A translation approach to portable ontology specifications. Knowledge Acquisit 1993, 5:199-220.
64. Noy NF, McGuinness DL. Ontology development 101: a guide to creating your first ontology. Standard knowledge systems laboratory technical report and Stanford medical informatics technical report, 2001. Available at: (Accessed May 13, 2011).
65. Smith L, Wilbur WJ. Retrieving definitional content for ontology development. Comp Biol Chem 2004, 28:387-391. doi:10.1016/j.compbiolchem.2004. 09.007.
66. Stevens R, Goble CA, Bechhofer S. Ontology-based knowledge representation for bioinformatics. Brief Bioinform 2000, 1:398-414.
67. Thomas DG, Pappu RV, Baker NA. NanoParticle ontology for cancer nanotechnology research. J Biomed Inform 2011, 44:59-74. doi:10.1016/j.jbi. 2010.03.001.
68. Ruttenberg A, Clark T, Bug W, Samwald M, Bodenreider O, Chen H, Doherty D, Forsberg K, Gao Y, Kashyap V, et al. Methodology-advancing translational research with the semantic web. BMC Bioinform 2007, 8(Suppl 3):S2. doi:10.1186/1471-2105-8-S3-S2.
69. Noy NF, Shah NH, Whetzel PL, Dai B, Dorf M, Griffith N, Jonquet C, Rubin DL, Storey MA, Chute CG, et al. BioPortal: ontologies and integrated data resources at the click of a mouse. Nucleic Acids Res 2009, 37:W170-W173. doi:10.1093/Nar/Gkp440.
70. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. Gene Ontology: tool for the unification of biology. Nat Genet 2000, 25:25-29.
71. Degtyarenko K, De Matos P, Ennis M, Hastings J, Zbinden M, McNaught A, Alcantara R, Darsow M, Guedj M, Ashburner M. ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res 2008, 36:D344-D350. doi:10. 1093/Nar/Gkm791.
72. de Matos P, Alcantara R, Dekker A, Ennis M, Hastings J, Haug K, Spiteri I, Turner S, Steinbeck C. Chemical entities of biological interest: an update. Nucleic Acids Res 2010, 38:D249-D254. doi:10.1093/Nar/Gkp886.
73. Rosse C, Mejino JLV. A reference ontology for biomedical informatics: the foundational model of anatomy. J Biomed Inform 2003, 36:478-500. doi:10. 1016/j.jbi.2003.11.007.
74. Sprague J, Clements D, Conlin T, Edwards P, Frazer K, Schaper K, Segerdell E, Song PR, Sprunger B, Westerfield M. The zebrafish information network (ZFIN): the zebrafish model organism database. Nucleic Acids Res 2003, 31:241-243. doi:10.1093/Nar/Gkg027.
75. Smith B, Ashburner M, Rosse C, Bard J, Bug W, Ceusters W, Goldberg LJ, Eilbeck K, Ireland A, Mungall CJ, et al. The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. Nat Biotechnol 2007, 25:1251-1255. doi:10.1038/Nbt1346.
76. Bada M, Hunter L. Desiderata for ontologies to be used in semantic annotation of biomedical documents. J Biomed Inform 2011, 44:94-101. doi:10.1016/j.jbi. 2010.10.002.
77. Rubin DL, Lewis SE, Mungall CJ, Misra S, Westerfield M, Ashburner M, Sim I, Chute CG, Solbrig H, Storey MA, et al. National Center for Biomedical Ontology: advancing biomedicine through structured organization of scientific knowledge. Omics-J Integ Biol 2006, 10:185-198.
78. Simon J, Dos Santos M, Fielding J, Smith B. Formal ontology for natural language processing and the integration of biomedical databases. Int J Med Inform 2006, 75:224-231. doi:10.1016/j.ijmedinf.2005.07. 015.
79. Smith B, Brochhausen M. Putting biomedical ontologies to work. Methods Inform Med 2010, 49:135-140. doi:10.3414/Me9302.
80. Harris MA. Developing an ontology. Methods Mol Biol 2008, 452:111-124. doi:10.1007/978-1-60327-159-2-5.
81. Shah NH, Jonquet C, Chiang AP, Butte AJ, Chen R, Musen MA. Ontology-driven indexing of public datasets for translational bioinformatics. BMC Bioinform 2009, 10(Suppl 2):S1. doi:10.1186/1471-2105-10-S2-S1.
82. Taylor CF, Field D, Sansone SA, Aerts J, Apweiler R, Ashburner M, Ball CA, Binz PA, Bogue M, Booth T, et al. Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nat Biotechnol 2008, 26:889-896. doi:10.1038/Nbt.1411.
83. Rayner TF, Rocca-Serra P, Spellman PT, Causton HC, Farne A, Holloway E, Irizarry RA, Liu JM, Maier DS, Miller M, et al. A simple spreadsheet-based, MIAME-supportive format for microarray data: MAGE-TAB. BMC Bioinform 2006, 7:489. doi:10.1186/1471-2105-7-489.
84. McNeil SE. Challenges for nanoparticle characterization. Methods Mol Biol 2011, 697:9-15. doi:10.1007/ 978-1-60327-198-1-2.
85. Klaessig F, Marrapese M, Abe S. Current perspectives in nanotechnology terminology and nomenclature. In: Murashov V, Howard J, eds. Nanotechnology Standards. New York: Springer; 2011.
86. Scientific committee on emerging and newly identified health risks, scientific basis for the definition of the term 'nanomaterial'. 2010.
87. Nel AE, Madler L, Velegol D, Xia T, Hoek EMV, Somasundaran P, Klaessig F, Castranova V, Thompson M. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009, 8:543-557. doi:10.1038/Nmat2442.
88. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001, 29:365-371.
89. Card JW, Magnuson BA. Proposed minimum characterization parameters for studies on food and food-related nanomaterials. J Food Sci 2009, 74:Vi-Vii. doi:10.1111/j.1750-3841.2009.01366.x.
90. Boverhof DR, David RM. Nanomaterial characterization: considerations and needs for hazard assessment and safety evaluation. Anal Bioanal Chem 2010, 396:953-961. doi:10.1007/s00216-009-3103-3.
91. Spellman PT, Miller M, Stewart J, Troup C, Sarkans U, Chervitz S, Bernhart D, Sherlock G, Ball C, Lepage M, et al. Design and implementation of microarray gene expression markup language (MAGE-ML). Genom Biol 2002, 3: 0046.1-0046.9.
92. Sansone SA, Rocca-Serra P, Brandizi M, Brazma A, Field D, Fostel J, Garrow AG, Gilbert J, Goodsaid F, Hardy N, et al. The first RSBI (ISA-TAB) workshop: "Can a Simple Format Work for Complex Studies?". Omics-J Integ Biol 2008, 12:143-149. doi:10.1089/omi.2008.0019.
93. Lopez-Alonso V, Hermosilla-Gimeno I, Lopez-Campos G, Maojo V, Martin-Sanchez FJ. Action GRID: assessing the impact of nanotechnology on biomedical informatics. AMIA Annu Symp Proc 2008, 1046.